genekor

21 November, 2024

Pancreatic cancer: How a simple blood draw can give an early diagnosis?

Dr. George Nasioulas, Scientific Director of Genekor Medical S.A. and Molecular Biologist, PhD gave an interview on Shape.gr about liquid biopsies and how they change the prognosis of pancreatic cancer. Pancreatic […]

5 November, 2024

Claudin 18.2 (CLDN 18.2): New Test at Genekor’s Pathology Laboratory for Patients with Advanced Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction

Genekor’s Pathology Laboratory now offers the Claudin 18.2 (CLDN 18.2) test, used to administer Zolbetuximab in combination with chemotherapy for patients with advanced or metastatic gastric adenocarcinoma and gastroesophageal junction […]

4 October, 2024

FRα: New Test at Genekor’s Pathology Laboratory for Targeted Therapy of Ovarian Cancer

The FRα test is performed for the administration of mirvetuximab soravtansine and is aimed at patients with platinum-resistant ovarian cancer who are FRα-positive and have received 1-3 lines of therapy. […]

11 September, 2024

New Study: “The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory”

The application of next-generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of developing new malignancies. The […]

3 September, 2024

New Pathology Laboratory Genekor

Genekor announces the opening of our new pathology laboratory. Genekor’s experienced and qualified staff is here to provide you with the most reliable and valid results to enhance your efforts […]

12 June, 2024

New Study: “The importance of pre-and post-genetic counselling for genetic testing in hereditary cancer “

Genekor participated again this year in the European Human Genetics Conference 2024 held in Berlin, where Dr. Konstantinos Agiannitopoulos, Molecular Biologist, Ph.D and Group Leader of Genekor’s Hereditary Cancer Group, […]

24 May, 2024

New Study: Neuroendocrine Breast Tumors: Could Multigene Assays Help in Guiding Treatment Decisions? Case Presentation

Breast cancer remains the most common type of cancer among women worldwide and remains the leading cause of death. Neuroendocrine breast cancer (NBC), a rare subtype that occurs in less […]

17 May, 2024

A revolution in early cancer diagnosis, with pioneering non-invasive molecular tests that harness Artificial Intelligence.

There are rapid developments in the field of early diagnosis of many cancers. Pioneering molecular tests, which also use AI, are now available in our country and can change the […]

26 April, 2024

Genekor’s participation in the 2-day Scientific Meeting on Cardiac Amyloidosis and Genetic Cardiovascular Diseases

Genekor Medical S.A. actively participated in the 2-day Scientific Meeting on Cardiac Amyloidosis and Genetic Cardiopathies on April 19 and 20 at the Cotsen Auditorium of the American School of […]

Search